Abstracts tagged "pathogenesis and proteomics"

Abstract Number: 2337 • 2017 ACR/ARHP Annual Meeting
Novel Serum Broad-Based Proteomic Discovery Analysis Identifies Proteins and Pathways Dysregulated in Juvenile Dermatomyositis (JDM) and Myositis Autoantibody Groups
Hanna Kim¹, Angélique Biancotto², Foo Cheung³, Terrance P. O'Hanlon⁴, Ira N. Targoff⁵, Yan Huang⁶, Frederick W Miller⁴, Raphaela Goldbach-Mansky⁶ and Lisa G Rider⁴, ¹Pediatric Translational Research Branch, NIAMS/NIH, Bethesda, MD, ²Center for Human Immunology, Autoimmunity and Inflammation (CHI), NHLBI, NIH, Bethesda, MD, ³Center for Human Immunology Autoimmunity and Inflammation (CHI), NHLBI, NIH, Bethesda, MD, ⁴Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, ⁵VA Medical Center, University of Oklahoma Health Sciences Center, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Translational Autoinflammatory Disease Studies (TADS), Laboratory of Clinical Investigation and Microbiology (LCIM), NIAID/NIH, Bethesda, MD
Background/Purpose: Juvenile dermatomyositis (JDM) is a complex heterogeneous autoimmune disease. Myositis-specific autoantibodies (MSAs), present in up to 80% of JDM patients, help define distinct phenotypes…
Abstract Number: 16 • 2017 Pediatric Rheumatology Symposium
Novel Serum Broad-Based Proteomic Discovery Analysis Identifies Proteins and Pathways Dysregulated in Juvenile Dermatomyositis (JDM) Myositis Autoantibody Groups
Hanna Kim¹, Angélique Biancotto², Foo Cheung³, Terrance P. O'Hanlon⁴, Ira N. Targoff⁵, Yan Huang⁶, Frederick Miller⁴, Raphaela Goldbach-Mansky⁶ and Lisa G. Rider⁴, ¹Pediatric Translational Research Branch, NIAMS/NIH, Bethesda, MD, ²Center for Human Immunology, Autoimmunity and Inflammation (CHI), NHLBI, NIH, Bethesda, MD, ³Center for Human Immunology Autoimmunity and Inflammation (CHI), NHLBI, NIH, Bethesda, MD, ⁴Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, ⁵VA Medical Center, University of Oklahoma Health Sciences Center, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Translational Autoinflammatory Disease Studies (TADS), NIAID, NIH, Bethesda, MD
Background/Purpose: Juvenile dermatomyositis (JDM) is a complex heterogeneous autoimmune disease. Myositis-specific autoantibodies (MSAs), present in up to 80% of JDM patients, help define distinct phenotypes…
Abstract Number: 780 • 2014 ACR/ARHP Annual Meeting
Novel Roles for Zyxin in the Pathogenesis of Giant Cell Arteritis
Rie Karasawa¹, Paul A. Monach², Mayumi Tamaki¹, Takahiro Okazaki³, Masamichi Oh-Ishi⁴, Yoshio Kodera⁴, Toshiko Sato¹, Shoichi Ozaki⁵, Kaiyu Jiang⁶, Kazuo Yudoh¹, James N. Jarvis⁷ and Peter A. Merkel⁸, ¹Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki, Japan, ²Section of Rheumatology, Vasculitis Center, Boston University School of Medicine, Boston, MA, ³Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ⁴School of Science, Kitasato University, Sagamihara, Japan, ⁵Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ⁶415 Carmen Road, Apt. 1, The University at Buffalo, Buffalo, NY, ⁷Pediatrics, The University at Buffalo, Buffalo, NY, ⁸Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose �:The mechanisms of the blood vessel injury in giant cell arteritis (GCA), a systemic vasculitis characterized by inflammation of large- and medium-sized vessels, remain…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].